Journal of Investigative Dermatology — Journal Profile & Submission Links
Elsevier BV · ISSN-L 0022-202X
Source-backed journal profile with OpenAlex metadata and links to official submission resources for Journal of Investigative Dermatology.
This page provides a source-backed journal profile and links to official submission resources. Journal instructions can change. Always verify article types, formatting, fees, ethics requirements, and submission rules on the official journal website before submitting.
Official links
- Journal homepage
- www.sciencedirect.com/journal/journal-of-investigative-derma…
- Author guidelines
- www.sciencedirect.com/journal/journal-of-investigative-derma…
- Submission portal
- mc.manuscriptcentral.com/jid
Catalog scope notes
The Journal of Investigative Dermatology (JID) publishes high impact reports describing original research related to all aspects of cutaneous biology and skin disease. Descriptions of important findings that result from basic, translational, or clinical research are appropriate for submission. Clinical research can include, but is not limited to, interventional trials, genetic studies, epidemiology, and health services research. The JID places a high priority on publication of new insights into basic cutaneous biology, disease pathogenesis, and treatment. Reports that describe a new methodology, technique, or tool in combination with mechanistic insights into the problem that is being investigated are encouraged. It is possible that occasional descriptions of novel technology, methodology, or resources that are of special interest or utility to JID readers could be competitive for publication, even in the absence of new mechanistic insights. Reports describing novel variants in known genes with no new mechanistic data will not be reviewed. Case reports or case series, unless they provide new biologic insights, are rarely appropriate for submission. Purely hypothesis generating clinical research such as analysis of case reports, pharmacovigilance reports (for example, analyses of FAERS), unless truly novel, or accompanied with hypothesis testing approaches (e.g., cohort, case-control, clinical trial, and/or mechanistic laboratory studies) are not within the JID Scope. Clinical research using administrative claims or electronic medical record data (for example, TriNetX) should have evidence that the codes validly represent the variables being studied and that the data are complete enough to yield valid inferences. Standard features of the Journal include Original Articles, Review Articles, and Letters to the Editor. Perspectives and Commentaries are invited by the Editorial Board. All articles are peer reviewed prior to acceptance and publication, and some invited articles may ultimately not be accepted for publication. Online features enhance JID content, making it more relevant and accessible, especially to non-scientists, trainees, and clinician-educators.
Catalog source: scimago. This is not a copy of the publisher's author instructions.
Submission & timeline
- Submission portal
- mc.manuscriptcentral.com/jid
- Average review time
- Information not currently available.
- Acceptance rate
- Information not currently available.
- Article types accepted
- Information not currently available.
- Publication frequency
- Information not currently available.
General pre-submission checks for medical manuscripts
Generic checklist only — not journal-specific requirements.
- Confirm scope fit and intended article type on the official journal site.
- Abstract structure matches the journal's current requirements.
- Ethics approval and trial registration statements are complete.
- Informed consent and patient privacy statements are in place.
- Reporting guideline compliance (e.g. CONSORT, STROBE, PRISMA) as applicable.
- Reference style and citation limits per official guidelines.
- Figures and tables meet resolution, labeling, and count limits.
- Cover letter addresses novelty, fit, and required declarations.
- Conflicts of interest statement included.
- Funding statement included.
- Data availability statement included when required.
